Oxygenation Inhibits the Physiological Tissue-Protection Mechanism and Thereby Exacerbates Acute Inflammatory Lung Injury

Manfred Thiel1,2, Alexander Chouker1,2, Akio Ohta1,3, Edward Jackson4, Charles Caldwell1, Patrick Smith1, Dmitry Lukashev1,3, Iris Bittmann5, Michail V. Sitkovsky1,3*

1 Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 2 Clinic of Anaesthesiology, University of Munich, Germany, 3 New England Inflammation and Tissue Protection Institute, Northeastern University, Boston, Massachusetts, United States of America, 4 Pharmacology/Medicine Pittsburgh, University of Pittsburgh School of Medicine, Pennsylvania, United States of America, 5 Pathology, Klinikum Grosshadern, University of Munich, Germany

Acute respiratory distress syndrome (ARDS) usually requires symptomatic supportive therapy by intubation and mechanical ventilation with the supplemental use of high oxygen concentrations. Although oxygen therapy represents a life-saving measure, the recent discovery of a critical tissue-protecting mechanism predicts that administration of oxygen to ARDS patients with uncontrolled pulmonary inflammation also may have dangerous side effects. Oxygenation may weaken the local tissue hypoxia-driven and adenosine A2A receptor (A2AR)-mediated anti-inflammatory mechanism and thereby further exacerbate lung injury. Here we report experiments with wild-type and adenosine A2AR-deficient mice that confirm the predicted effects of oxygen. These results also suggest the possibility of iatrogenic exacerbation of acute lung injury upon oxygen administration due to the oxygenation-associated elimination of A2AR-mediated lung tissue-protecting pathway. We show that this potential complication of clinically widely used oxygenation procedures could be completely prevented by intratracheal injection of a selective A2AR agonist to compensate for the oxygenation-related loss of the lung tissue-protecting endogenous adenosine. The identification of a major iatrogenic complication of oxygen therapy in conditions of acute lung inflammation attracts attention to the need for clinical and epidemiological studies of ARDS patients who require oxygen therapy. It is proposed that oxygen therapy in patients with ARDS and other causes of lung inflammation should be combined with anti-inflammatory measures, e.g., with inhalative application of A2AR agonists. The reported observations may also answer the long-standing question as to why the lungs are the most susceptible to inflammatory injury and why lung failure usually precedes multiple organ failure.

Introduction

Many clinical conditions, including aspiration, trauma, and hemorrhagic shock, are frequently followed by pulmonary and systemic infectious and septic complications that lead to pulmonary dysfunction and subsequent lung failure. Acute lung injury or its more severe form, the acute respiratory distress syndrome (ARDS), occur with a frequency of approximately 130,000 cases and more than 50,000 deaths from ARDS per year in the United States alone [1]. Intubation with mechanical ventilation represent one of the most widely used prophylactic and therapeutic clinical interventions to counteract the insufficient pulmonary oxygen-delivering capacity in patients who suffer from severe lung inflammation. Although the majority of patients respond well to oxygen therapy, and oxygen toxicity is an uncommon occurrence in intensive care medicine [2], there remains the possibility that oxygen therapy may be suboptimal in ARDS patients, as it may promote deleterious pulmonary inflammation, which fuels this disease process. Since the magnitude and duration of lung inflammation has been shown to determine the final outcome of ARDS patients [3], it is important to carefully evaluate the possible adverse effects of oxygen on inflammatory processes.

We assumed that lung tissues are protected from overactive immune cells by the same hypoxia-driven mechanism and immunosuppressive adenosine A2A receptor (A2AR)-mediated mechanism that was recently shown to play a critical role in the down-regulation of inflammation and tissue damage in different models [4–7]. Accordingly, it is likely that bacterial toxin-activated immune cells (e.g., granulocytes) cause collateral lung tissue damage with impairment of the local microcirculation and blood supply, thereby contributing to the pathogenesis of acute lung injury. The ensuing tissue...

damage-associated hypoxia facilitates the accumulation of extracellular adenosine [8–12], which then triggers the activation of immunosuppressive A2ARs on activated immune cells and causes the accumulation of immunosuppressive intracellular cyclic adenosine 3′,5′-monophosphate (cAMP). This cAMP, in turn, inhibits signaling pathways that are required for synthesis and secretion of proinflammatory and cytotoxic mediators by immune cells, and thereby protects remaining healthy tissues from continuing immune damage. Since this physiological tissue-protecting mechanism depends on the hypoxia-produced extracellular adenosine [8–12], and since the oxygenation of lungs in intubated patients is performed to increase oxygen tension—with the goal of abolishing the hypoxia but disrupting the adenosine accumulation—we reasoned that such interruption of the hypoxia → adenosine → A2AR pathway by oxygenation could lead to a disengagement of the critical tissue-protecting mechanism and to an unintended exaggeration of inflammatory lung damage (iatrogenic disease). Thus, oxygenation may eliminate this lung-protecting pathway and thereby contribute to pulmonary complications.

We confirm our prediction in several in-vivo models of lung infection and inflammation and report that oxygenation does indeed strongly exacerbate inflammatory lung damage and accelerate death in mice by the interruption of the hypoxia → adenosine → A2AR pathway. We also suggest an effective and feasible therapeutic countermeasure to prevent deleterious effects of oxygenation: Exogenously added synthetic A2AR agonist compensated for the loss of endogenously formed adenosine in inflamed lungs of oxygenated mice, and thereby prevented inflammatory lung injury and prevented death.

**Results**

**Exacerbation of Inflammatory Lung Injury and Death in Oxygenated Mice**

To test our prediction, we subjected mice to inhalation of combined toxins from gram-positive and gram-negative bacteria. In this model of polymicrobial lung infection, intratracheal (IT) injection of both lipopolysaccharide (LPS) and staphylococcal enterotoxin B (SEB) strongly potentiates their toxicity [13].

The results of these assays confirmed the prediction of exaggerated lung injury in mice in conditions that mimic therapeutic oxygenation, and this is reflected in the dramatic increases in inflammatory lung damage in different in vivo and ex vivo assays (Figures 1 and 2). Five times more mice with inflamed lungs died after exposure to 100% oxygen than those left at 21% ambient oxygen tension (Figure 1). This was further confirmed by a much more pronounced increase in the alveolocapillary permeability and severe overall impairment of lung gas exchange, as evidenced by the increase in the amount of protein recovered from the alveolar space by bronchoalveolar lavage (BAL), as well as by the decrease in arterial oxygen partial pressure (pO2) values of previously oxygen-exposed mice when returned to normal atmosphere (Figure 2A). Although exposure of mice to 100% oxygen alone (with no toxin inhalation) did induce a small accumulation of BAL fluid protein, the magnitude of that effect could not account for the dramatic increases in lung vascular permeability and impairment of lung gas exchange when both toxins and oxygenation were used (Figure 2A).

The exacerbation of inflammatory lung injury was also observed when mice were exposed to 60% oxygen, a concentration considered in human patients to be fairly safe. Compared to toxin-injected animals breathing 21% oxygen, those breathing 60% oxygen accumulated much more exudate proteins in the alveolar spaces and exhibited impaired arterial blood oxygen tensions (Figure 2B). Exposure of toxin-injected mice to 60% oxygen, however, did not result in death in the short-term assays we used.

These observations confirmed the prediction that inflamed lung injury is exacerbated by oxygenation; however, the development of therapeutic countermeasures requires testing of the validity of our underlying assumptions and conclusive identification of the molecular mechanisms of these proinflammatory effects of oxygen.
Oxygen Exacerbates Acute Lung Injury

The observed effects of oxygenation could not be accounted for by direct toxic effects of oxygen, since these effects of oxygen take much longer to manifest [2, 14, 15] and therefore are unlikely to fully account for the dramatic lung injury observed in our short-term experiments (Figures 1 and 2).

To test whether oxygen enhances inflammatory tissue damage by eliminating the hypoxia → adenosine → A2AR pathway, which is hypothesized as being responsible for protecting inflamed lungs and down-regulating neutrophils, we (i) determined the role of neutrophils in inflammatory lung injury, (ii) tested for A2AR expression on these cells to demonstrate their susceptibility to modulation by endogenously produced adenosine, (iii) analyzed the degree of inflammatory lung tissue damage in A2AR gene-deficient mice or in wild-type mice treated with highly selective pharmacologic antagonists for A2ARs, and (iv) tested whether the hypoxia has a lung-protective role and whether there is a direct linkage between hypoxia (upstream) and A2ARs (downstream) in the proposed lung-protective hypoxia → A2AR pathway.

To diminish the suffering of animals with severely inflamed and damaged lungs, in the experiments described in the next section we used the less-severe lung injury model established by the injection of LPS alone instead of the polymicrobial (SEB + LPS) model of lung damage.

Neutrophils Are Involved in Inflammatory Lung Injury and Are Inhibited by A2ARs

The observed effects of oxygenation could not be accounted for by direct toxic effects of oxygen, since these effects of oxygen take much longer to manifest [2, 14, 15] and therefore are unlikely to fully account for the dramatic lung injury observed in our short-term experiments (Figures 1 and 2).

To answer the question of whether murine neutrophils are susceptible to inhibitory effects of endogenously produced adenosine via A2AR signaling, we characterized the effects of increasing concentrations of the highly specific A2AR agonist CGS21680 on the oxygen radical production of granulocytes taken from the blood of healthy mice. Surprisingly, respiratory burst activity of such “naïve” granulocytes was only poorly inhibited by A2AR signaling (Figure 4A, left graph). Therefore it was important to test whether “in vivo-activated” granulocytes isolated from inflamed lungs of IT LPS-injected mice might have up-regulated their A2AR expression. As expected, significant up-regulation of A2AR was observed in experiments in which CGS21680 greatly enhanced the chemotactic peptide N-formyl-methionyl-leu- cyl-phenylalanine (fMLP)-stimulated cAMP production of in vivo-activated neutrophils isolated from inflamed lungs from wild-type mice, but not of naïve granulocytes obtained from the bone marrow of healthy wild-type control mice (Figure 4B, left graph). In a genetic control, the cAMP increase was absent in in vivo-activated granulocytes from A2AR gene-deficient mice (Figure 4B, right graph). In a genetic control, the cAMP increase was absent in in vivo-activated granulocytes from A2AR gene-deficient mice (Figure 4B, right graph). In a genetic control, the cAMP increase was absent in in vivo-activated granulocytes from A2AR gene-deficient mice (Figure 4B, right graph). In a genetic control, the cAMP increase was absent in in vivo-activated granulocytes from A2AR gene-deficient mice (Figure 4B, right graph). Results of parallel assays confirmed increased expression of A2AR on activated granulocytes, since CGS21680 inhibited the functional response of in vivo-activated granulocytes (i.e., as evidenced by the production of...
tissue-damaging reactive oxygen species) much more strongly than in naive cells (Figure 4A, right graph). When compared to the several-fold increase in A2AR mRNA expression levels in inflammatory granulocytes from mice exposed to 21% oxygen, these levels were up-regulated to a much lesser extent in mice breathing 100% oxygen. As in the first experiment, no changes were observed in A3 mRNA expression, while expression of A2B receptors showed changes similar to those of A2AR mRNA (unpublished data). Interestingly, the expression of A1 mRNA levels was increased in inflammatory lung granulocytes obtained from hyperoxic animals. Thus, the decreased up-regulation of A2AR-specific mRNA that was observed in parallel with an increased A1 receptor-specific mRNA expression in inflammatory granulocytes from mice breathing pure oxygen is in support of hyperoxic exacerbation of lung injury.

A2ARs Protect Lung Tissue from Inflammatory Damage

The genetic evidence for the critical role of A2AR in lung protection was provided by the observation of many more PMNs in BAL from A2AR-deficient mice than in BAL from similarly treated wild-type mice (Figure 5A). This was accompanied by an increase in lung vascular permeability as reflected by enhanced BAL protein levels in A2AR-deficient mice and a decrease in overall lung function, which was manifested by a decrease in arterial blood oxygen tension as compared to wild-type mice.

In agreement with the genetic evidence in Figure 5A, similar proinflammatory changes in numbers of granulocytes, levels of protein, and values of lung gas exchange were observed after pharmacological inactivation of A2AR with the antagonist ZM241385 (Figure 5B).

These observations establish that the A2AR is critical in limiting inflammatory lung injury; even higher lung injury would have resulted from the inflammatory stimuli we used, were it not for the lung protection in wild-type mice due to the inhibition of neutrophils by a functional hypoxia A2AR pathway.

Hypoxia Down-Regulates Neutrophils and Protects Lung Tissue from Inflammatory Damage

To test whether anti-inflammatory lung-protective effects can be induced in mice by allowing them to breathe a hypoxic gas mixture, LPS-injected wild-type mice were exposed to 10% oxygen. Although this oxygen concentration was sublethal for LPS-injected mice, we chose to study the effects of this degree of hypoxia because 15% of ARDS patients die from therapy-refractory hypoxemia [18]. Accordingly, some deaths occurred in IT LPS-injected mice at hour 4–7 of hypoxic exposure. In the majority of surviving mice (over 90%), however, hypoxia for 48 h strongly inhibited acute neutrophilic inflammation and led to overall better lung protection compared to mice kept at 21% oxygen. This improvement was evidenced by a decreased pulmonary sequestration of PMNs (Figure 6), inhibition of their capability to produce oxygen-reactive metabolites (Figure 6A), decreased protein accumulation (Figure 6B), and better lung function as reflected in higher arterial Po2 levels (Figure 6A). This conclusion was further confirmed by histological studies (Figure 6C) that revealed not only a decrease in PMN sequestration, but also a significant decrease in parameters of

tissue-damaging reactive oxygen species much more strongly than in naive cells (Figure 4A, right graph).

The results of mRNA expression studies were in agreement with above functional studies of adenosine receptors, and a much stronger increase in A2AR mRNA levels was observed in in vivo-activated PMNs than in naive cells, with only small changes in A1 receptor mRNA expression in the first experiment (Figure 4C, left graph). These findings were further confirmed in a second experiment in which the effect of 100% oxygen was compared to that of normal atmosphere (Figure 4C, right graph). When compared to the several-fold increase in A2AR mRNA expression levels in inflammatory granulocytes from mice exposed to 21% oxygen, these levels were up-regulated to a much lesser extent in mice breathing 100% oxygen. As in the first experiment, no changes were observed in A3 mRNA expression, while expression of A2B receptors showed changes similar to those of A2AR mRNA (unpublished data). Interestingly, the expression of A1 mRNA levels was increased in inflammatory lung granulocytes obtained from hyperoxic animals. Thus, the decreased up-regulation of A2AR-specific mRNA that was observed in parallel with an increased A1 receptor-specific mRNA expression in inflammatory granulocytes from mice breathing pure oxygen is in support of hyperoxic exacerbation of lung injury.

A2ARs Protect Lung Tissue from Inflammatory Damage

The genetic evidence for the critical role of A2AR in lung protection was provided by the observation of many more PMNs in BAL from A2AR-deficient mice than in BAL from similarly treated wild-type mice (Figure 5A). This was accompanied by an increase in lung vascular permeability as reflected by enhanced BAL protein levels in A2AR-deficient mice and a decrease in overall lung function, which was manifested by a decrease in arterial blood oxygen tension as compared to wild-type mice.

In agreement with the genetic evidence in Figure 5A, similar proinflammatory changes in numbers of granulocytes, levels of protein, and values of lung gas exchange were observed after pharmacological inactivation of A2AR with the antagonist ZM241385 (Figure 5B).

These observations establish that the A2AR is critical in limiting inflammatory lung injury; even higher lung injury would have resulted from the inflammatory stimuli we used, were it not for the lung protection in wild-type mice due to the inhibition of neutrophils by a functional hypoxia A2AR pathway.

Hypoxia Down-Regulates Neutrophils and Protects Lung Tissue from Inflammatory Damage

To test whether anti-inflammatory lung-protective effects can be induced in mice by allowing them to breathe a hypoxic gas mixture, LPS-injected wild-type mice were exposed to 10% oxygen. Although this oxygen concentration was sublethal for LPS-injected mice, we chose to study the effects of this degree of hypoxia because 15% of ARDS patients die from therapy-refractory hypoxemia [18]. Accordingly, some deaths occurred in IT LPS-injected mice at hour 4–7 of hypoxic exposure. In the majority of surviving mice (over 90%), however, hypoxia for 48 h strongly inhibited acute neutrophilic inflammation and led to overall better lung protection compared to mice kept at 21% oxygen. This improvement was evidenced by a decreased pulmonary sequestration of PMNs (Figure 6), inhibition of their capability to produce oxygen-reactive metabolites (Figure 6A), decreased protein accumulation (Figure 6B), and better lung function as reflected in higher arterial Po2 levels (Figure 6A). This conclusion was further confirmed by histological studies (Figure 6C) that revealed not only a decrease in PMN sequestration, but also a significant decrease in parameters of
lung tissue damage as evidenced by the 7-fold reduction of the lung injury score (LI; Figure 6C).

Taken together, these data strongly suggest that tissue hypoxia is important in protecting pulmonary tissues from additional inflammatory damage.

Hypoxia and A2AR-Triggered Signaling Function in the Same Lung Tissue-Protecting Pathway

It was important to establish whether inflamed and hypoxic lung tissues are protected by enhanced adenosine formation and subsequent A2AR engagement or by an anti-inflammatory role of a yet-to-be-uncovered hypoxia-induced endogenous anti-inflammatory molecule X-mediated pathway. To distinguish between these two possibilities, we tested the effects of genetic deficiency of the A2AR on inflammatory lung injury in hypoxic conditions.

Exposure of healthy wild-type mice to 10% oxygen resulted in a drop of arterial blood pO2 values to levels observed during severe hypoxemia (Figure 7A, left graph). As a result of insufficient systemic oxygen delivery and resulting hypoxia, breathing of 10% oxygen caused an increase in production of endogenous adenosine, shown by the rise of extracellular plasma concentrations of the nucleoside (Figure 7A, right graph).

Hypoxic (10%) oxygen was also expected to provide an important readout of the degree of lung injury by the level of survival in the mice. In our experiments, the dose of LPS injection induced much higher levels of lung injury in A2AR-deficient mice than in control wild-type mice (see Figure 5), but neither wild-type or A2AR deficient mice died if they were kept at 21% oxygen at these levels of lung injury.

Different outcome with respect to death rates were expected, if A2AR-deficient and wild-type mice with LPS-inflamed lungs were kept at 10% oxygen. We reasoned that...
In contrast, these treatments would not result in pronounced lethality in lung-inflamed wild-type mice at 10% oxygen tension, because wild-type mice benefit from their lung-protecting hypoxia → A2AR pathway and would have much larger portions of still-healthy lungs left to ensure sufficient oxygen supply to tissues.

Accordingly, we predicted that the majority of A2AR genetically deficient mice would die at 10% oxygen, while the majority of wild-type mice would survive. This prediction was based on the assumption that the hypoxia → A2AR pathway is nonredundant and would not be substituted by another hypoxia → “X” molecule receptor pathway.

These observations leave no doubt that deficiency in the A2AR did not cause death per se, because all mice survived (unpublished data).

Interestingly, the increase in hypoxia A2AR-controlled TNF-α levels was accounted for by local accumulation in the lung, because BAL concentrations of this cytokine were on average ten times higher than in the systemic circulation, although the BAL volume was at least three times higher than that of a mouse’s blood. By contrast, levels of IL-6 and MIP-2α were much higher in the systemic circulation, suggesting that TNF-α BAL levels may serve as a useful marker for lung inflammation (Figure 7C). Moreover, the results shown in Figure 7D support the view that pulmonary proinflammatory cytokine TNF-α levels are indeed under the negative control of the hypoxia → A2AR pathway. This is supported by data showing no differences in BAL TNF-α concentrations between A2AR gene-deficient mice breathing either 10% or 100% oxygen. In contrast, the BAL TNF-α concentrations were significantly lower in hypoxic wild-type mice (with functioning hypoxia → adenosine → A2AR pathway) than in mice breathing pure oxygen (Figure 7D).

Taken together, these experiments support the view that both hypoxia and A2AR are needed to down-regulate lung inflammation, and that oxygenation exacerbates lung injury due to interruption of the tissue-protecting hypoxia → A2AR anti-inflammatory pathway. Thus, these observations leave no room for yet another lung tissue-protecting hypoxia → X receptor signaling pathway in tested experimental conditions. This knowledge suggested a direct and effective therapeutic countermeasure to reap benefits of oxygenation.

**Figure 5.** Evidence for the Critical Role of Immunosuppressive A2AR in Lung Protection from Inflammatory Damage

(A) In A2AR gene-deficient mice, number of PMNs (left graph) and amount of protein recovered (center graph) 48 h after IT LPS injection by BAL was significantly higher than in similarly treated wild-type control mice, reflecting increased lung damage in the absence of A2AR. The arterial oxygen tension (right graph) was lower in A2AR gene-deficient mice as compared with wild-type mice.

(B) Pharmacologic inactivation of A2AR leads to exacerbated tissue damage, as reflected by increased number of PMNs (left graph) and protein levels (center graph) in the BAL fluid obtained after 48 h. In parallel experiments, the A2AR antagonist decreased lung function (right graph) as compared to untreated wild-type mice, in agreement with results of experiments with A2AR gene-deficient mice. DOI: 10.1371/journal.pbio.0030174.g005

under these conditions the A2AR-deficient mice would have much more pronounced pulmonary inflammation and hence less healthy lung tissues left to adequately oxygenate vital organs. Thus, the interruption of the hypoxia → A2AR pathway and the resulting uninhibited inflammatory processes and increased lung damage would lead to accelerated death of A2AR-deficient mice in 10% oxygen.
(right graph) compared to a control group of endotoxin-treated mice that were kept at ambient (21%) oxygen. To standardize conditions, the arterial blood samples were taken 15 min after return of the previously hypoxia-exposed animals to normal atmosphere.

(b) Treatment by a shorter period of hypoxia attenuates PMN sequestration (left graph) and lung vascular permeability (right graph). Hypoxic treatment of mice even for only 24 h was sufficient to delay PMN sequestration and to diminish the increase in lung vascular permeability.

(c) Histologic evidence for the hypoxic inhibition of pulmonary PMN sequestration. Quantitative analysis of lung slices by a pathologist blinded to the experimental design revealed inhibition of PMN sequestration in IT LPS-injected mice following 4-h exposure to hypoxia. Hypoxia not only attenuated PMN accumulation, but the lung tissue damage was also significantly decreased as assessed by the LIS (n = 9, mean ± standard deviation). The representative H&E-stained slices in the right two photomicrographs show less intravascular granulocyte sequestration, less thickening of the alveolo-capillary membrane, and almost no granulocytes in the alveolar spaces as compared to IT endotoxin-injected animals breathing 21% O2. These observations demonstrate that hypoxia also inhibited the transmigration of granulocytes from capillaries into the alveolar spaces.

DOI: 10.1371/journal.pbio.0030174.g006

An A2AR Agonist Compensates for the Loss of Lung-Protective Mechanisms and Prevents Death

Figure 8 shows that IT injections of the selective A2AR agonist CGS21680 significantly inhibited lung injury in LPS-treated mice. This treatment led to (i) significantly decreased accumulation of PMNs (Figure 8A), (ii) reduced production of reactive oxygen metabolites (Figure 8A), (iii) less-pronounced increases in lung vascular permeability (Figure 8B), and (iv) improved lung gas exchange (Figure 8B). Histological examination of CGS21680-treated mice revealed that therapeutic effects of the agonist were similar to those of exposure of mice to hypoxia. CGS21680 treatment resulted in inhibition of pulmonary PMN sequestration (Figure 8C), and—as shown for hypoxia above—was followed by a significant reduction of lung tissue damage as assessed by the 4-fold decrease in the LIS (Figure 8C).

Treatment with CGS21680 was effective even when applied in the more severe polymicrobial toxin model of lung injury (i.e., LPS + SEB); IT injections of this agonist under hyperoxic conditions rescued the majority of mice from oxygenation-induced death. The death rate was 80% among oxygenated mice with inflammatory lung injury in the control group, but dramatically less among those treated with the A2AR agonist (Figure 9).

Thus, the exogenously added, selective, synthetic A2AR agonist compensated for the loss of endogenously formed adenosine in oxygenated inflamed lungs, thereby decreasing lung injury and rescuing mice from death. In an important control, CGS21680 at the dosing regimen used to treat wild-type mice was proven to be selective, since it did not affect lung inflammation in A2AR gene-deficient mice (unpublished data).

Discussion

The oxygenation of hypoxic patients with impaired lung function is an important and life-saving therapeutic measure, but 15% of patients with ARDS still die from treatment-refractory hypoxia [18]. We here provide evidence supporting
the hypothesis that, in a mouse model of lung inflammation, while oxygenation relieves the immediate life-threatening consequences of hypoxemia, it also further exacerbates acute lung injury and even may lead to death due to the interruption of the critically important, nonredundant hypoxia → adenosine → A2AR-mediated lung-protecting pathway. This conclusion is supported by (i) the strong increase in lung inflammation and mortality after short-term exposure of mice to high and even to moderately elevated concentrations of oxygen (see Figures 1 and 2); (ii) the causative pathogenic role of PMNs in inflammatory lung injury (see Figure 3) and the up-regulation of A2AR expression in hypoxic lung inflammation; this experiment mimics the clinical situation in which lung inflammation increases to such severity that hypoxia occurs.

**Figure 7.** Hypoxia and Extracellular Adenosine A2AR Function in the Same Anti-Inflammatory, Lung Tissue-Protecting Pathway

(A) Effects of breathing hypoxic (10%) oxygen on arterial blood oxygen tension (left graph) and plasma adenosine concentration (right graph) in healthy wild-type mice. As a control, data are also shown for healthy mice breathing 21% and 100% oxygen.

(B) No survival of A2AR gene-deficient mice was observed in acute hypoxic lung injury. Wild-type and A2AR gene-deficient mice were injected IT with LPS and exposed to hypoxia (10%). While the majority of wild-type mice survived, all of the A2AR gene-deficient mice died, indicating that expression of A2AR is required for survival of hypoxic lung inflammation; this experiment mimics the clinical situation in which lung inflammation increases to such severity that hypoxia occurs.

(C) Significantly higher levels of pulmonary and systemic inflammatory cytokine production in hypoxic A2AR-deficient mice. Observations of survival were supported by significantly higher BAL and serum (Se) levels of inflammatory cytokines in hypoxic A2AR-deficient mice compared to hypoxic wild-type mice. Cytokines were determined 2 h after IT LPS injection, because A2AR-deficient mice started to die soon after LPS administration and thus could not be used in comparative studies with wild-type control mice. The early mortality of A2AR-deficient mice also did not allow the comparative determination of effects of hypoxia on other late markers of inflammation such as PMN accumulation, lung vascular permeability, and pulmonary gas exchange, which in wild-type mice need about 48 h to develop after IT endotoxin injection.

(D) Degree of inflammation is independent from level of oxygen in A2AR-deficient mice but not in wild-type mice. While BAL fluid TNF-α concentrations determined 2 h after IT LPS injection were significantly suppressed in hypoxic wild-type mice compared to animals breathing 100% oxygen, hypoxia had no effect on TNF-α BAL concentrations in A2AR gene-deficient mice, demonstrating that suppression of TNF-α formation by hypoxia is mediated through A2AR signaling.

DOI: 10.1371/journal.pbio.0030174.g007
expression on alveolar PMNs (see Figures 4); (iii) the critical role of A2AR in lung protection from enhanced accumulation of PMNs as well as more pronounced vascular permeability and stronger impairment of lung gas exchange in A2AR genetically deficient mice (see Figure 5A) and in A2AR antagonist-treated wild-type mice (see Figure 5B); (iv) the strong lung-protective effects of hypoxia by suppression of PMN emigration, PMN activation, lung vascular permeability, and impairment of gas exchange in wild-type mice (see Figure 6); (v) the evidence that hypoxia is upstream of A2ARs in the same anti-inflammatory, lung tissue-protecting pathway, as shown by the failure of the adenosine-producing (see Figure 7A) hypoxia to protect A2AR-deficient mice from death and excessive pulmonary TNF-α cytokine production (see Figure 7B–7D), and (vi) the confirmation of the hypoxia-elicited lung-protective effects in wild-type mice by the A2AR agonist CGS21680 (see Figure 8), which (vii) could rescue mice from hyperoxia-accelerated death (Figure 9).

By confirming the molecular mechanism of the predicted exacerbation of lung injury by oxygenation, this mechanism also offers a direct and effective preventive measure by compensating for the oxygenation-related loss of endogenous adenosine. Accordingly, we suggest the reevaluation of relevant ventilation and oxygenation protocols and the consideration of compensatory therapeutic treatments of oxygenated-inflamed lungs with A2AR agonists (reviewed in [7]) to prevent uninterrupted inflammatory lung damage (see Figure 8) and death (Figure 9). Other anti-inflammatory drugs alone or in combination with an A2AR agonist should be also considered in future refinements of this approach, because an A2AR agonist offers the advantage of pharmacologically restoring the physiological tissue-protecting pathway [4, 11, 12], which is unintentionally weakened by therapeutic oxygenation.

It is likely that these findings are most applicable to ARDS patients, although other clinical situations in which inflamed lungs are oxygenated should be also considered. The lungs of ARDS patients are known to be heterogeneously ventilated, leaving substantial lung areas hypoxic with up to 33% of total lung volume being nonaerated [21]. These are the most damaged and therefore hypoxic lung regions, where—counterintuitively—hypoxia may protect still-healthy surrounding lung tissues from the additional inflammatory
injury by promoting formation of extracellular adenosine [8–10] and strengthening the anti-inflammatory A2AR signaling pathway [4–7, 11, 12]. Supportive ventilation to increase lung tissue oxygen levels also eliminates the hypoxia-associated formation of anti-inflammatory endogenous adenosine, and this allows the unopposed continuation of the inflamed lung destruction. Thus, a necessary medical intervention (oxygenation of oxygen-deprived patients) may also cause an iatrogenic exacerbation of the very condition that led to the need for oxygenation in the first place. Such pathophysiological consequences of tissue oxygenation are expected to be most pronounced in collapsed hypoxic lung areas that would be recruited by any kind of ventilatory strategy [22].

In agreement with our findings are sporadic observations of effects of oxygenation in other clinical human protocols [23, 24] and experimental assays in animal models [25, 26]. For instance, intraoperative administration of 100% oxygen augmented proinflammatory cytokine production of alveolar macrophages within 2–8 h of the start of anesthesia and surgery in patients [23, 24]. Similarly, in animal models of lung injury, a synergistic action between infectious agents [25], bacterial toxins [26], or acid aspiration [27] and hypoxia was demonstrated and difficult to explain by direct oxygen toxicity. Indeed, the time periods of these effects were much too short for the manifestation of oxygen toxicity, which usually takes more than 64–72 h to become clinically apparent in mice [14]. Of note, in the same mouse strain (C57BL/6) that we used in our studies, breathing of pure oxygen did not result in death before the fourth day [15].

Although it is likely that synergy between lung-damaging noxious agents and oxygen is mediated by oxygen radicals [27], the elimination by oxygenation of the natural anti-inflammatory hypoxia → A2AR signaling pathway was not appreciated before, which may account for a significant proportion of inflammatory complications in patients.

Our observations of potent anti-inflammatory effects of hypoxia in lung injury (see Figures 6 and 7D) are in agreement with previously published effects of hypoxia, including significant attenuation of emigration of neutrophils to the site of inflammation in carrageenan-induced pleurisy [28], inhibition of granulocyte adhesion to endothelial cells [29], enhanced shedding of adhesion molecule CD11b from PMNs [30], and suppression of cytokine formation when PMNs are in contact with extracellular matrix proteins [31]. Use of cd39- and cd73-null animals revealed that extracellular adenosine produced through adenine nucleotide metabolism during hypoxia is a potent mechanism attenuating excessive tissue PMN accumulation [9]. Hypoxia was also shown to strongly inhibit production of MCP-1 [32], IL-1β [33], granulocyte-macrophage colony-stimulating factor [34], and induced down-regulation of co-signaling molecules (CD80) [35]. Hypoxia was further shown to cause decreased expression of Toll-like receptor 4 receptors by inhibiting translocation of activator protein 1 [36] and caused suppression of Escherichia coli-induced nuclear factor kB and activator protein 1 transactivation [37]. Finally, hypoxia was shown to stimulate phosphatidylinositol 3-kinase activity and thereby protect human lung microvascular endothelial cells and epithelial type II-like A549 cells from subsequent oxygen toxicity [38].

However, hypoxia was also shown to exert some proinflammatory effects in vitro [39] and in vivo [9, 40, 41] for time intervals ranging from 3 to 12 h, which may not reflect the long-term effects of hypoxia on inflammatory processes as assessed in our study.

Importantly, the virtually complete lung protection from the proinflammatory effects of 100% oxygen by an immunosuppressive A2AR agonist (Figure 9) supports the view that exacerbation of lung damage by 100% oxygen could be almost fully accounted for by immune mechanisms in addition to mechanical [42, 43] or radical-mediated mechanisms of lung injury [2]. It remains to be determined, however, whether the much longer time course of the direct toxicity of 100% oxygen in healthy, noninflamed lungs could be explained by the recruitment of immune cells [44], which then, in turn, would exacerbate the 100% oxygen-triggered lung tissue damage through prolongation of trauma-initiated inflammation.

Finally, the observations and conclusions of this report may have implications for the widely used therapeutic oxygen-
Oxygen Exacerbates Acute Lung Injury

Table 1. Determination of Lung Injury Score

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Degree of Severity</th>
<th>According to the thickness of alveolar septal membranes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial edema formation</td>
<td>M0 adherent to alveolar membranes, no intraalveolar accumulation in alveoli</td>
<td>M0 more frequently found in alveoli M0 most frequently found in groups in alveoli</td>
</tr>
<tr>
<td>Activation of M0</td>
<td>M0 start to lose contact with alveolocytes, single cells located</td>
<td></td>
</tr>
</tbody>
</table>

Activation of endothelial cells

| Endothelial cells are flat and adhere to alveolocytes | Hyperchromatic, enlarged nucleus | Hobnail phenomenon, cytoplasmic vacuoles | Pronounced hobnail phenomenon cytoplasmic vacuoles, start of cellular disintegration |

Leukocyte adhesion to endothelial cells

| None | Only a few leukocytes adhere | Groups of leukocytes adhere | Leukocytes adhere to entire vessel circumference and start to transmigrate |

Materials and Methods

**Mice.** Female 6- to 8-wk-old C57BL6 A2AR gene-deficient mice (N10) and age-matched wild-type mice were maintained in pathogen-free NIH animal facilities. The A2AR genotypes of mice were determined by Southern blot analysis as described previously [47]. All animal study protocols were approved by the NIH Animal Care and Use Committee.

**IT administration of LPS and SEB.** Female C57BL6 mice were anesthetized by isoflurane anesthesia. Using a modified transtracheal illumination technique [48], mice were nontraumatically intubated by intratracheal insertion of a 24-gauge catheter (Abbocath-T, Abbott Ireland, Ireland) via direct laryngoscopy. SEB was injected IT at a dose of 1 mg/kg body weight in a total volume of 50 μl per mouse. After IT injection of unconscious but spontaneously breathing mice, animals were held in an upright position for 15 s and then briefly shaken in all directions to ensure homogenous fluid dispersion in the lung. After 1 h, mice were anesthetized again with isoflurane and injected with LPS at a dose of 4 mg/kg body weight in a total volume of 50 μl per mouse. The injected fluid was dispersed by the same positioning maneuver as applied for the intrapulmonary distribution of SEB. Control, sham-treated mice were intubated and injected with only the solvent that was used to inject toxins, i.e., phosphate-buffered saline.

**LPS administration.** LPS was IT injected at a dose of 2 mg/kg body weight in a total volume of 50 μl per mouse under isoflurane anesthesia using the same technique as described above.

**Depletion of granulocytes in mice.** Mice were depleted in granulocytes by two IV injections of anti-GR-1 monoclonal antibody at a dose of 1 mg/kg body weight, administered 24 h before and briefly before IT injection of LPS. Control animals received isotype-matched antibody at the same dose and intervals.

In vivo administration of A2AR receptor agonist and antagonist. The A2AR agonist CGS21680 was dissolved in PBS and administered by IT injection at 0.1 mg/kg body weight in a total volume of 50 μl per mouse. IT injection of CGS21680 was repeated every 8 h until termination of the experiment. In control animals, the solvent of CGS21680, i.e., PBS only, was administered in the same way and on the same schedule. CGS21680 solution or solvent were injected within 15 min of administration of SEB and/or LPS in both models of lung injury. In studies using ZM214385, the A2AR antagonist was injected subcutaneously at a dose of 10 mg/kg body weight every 6 h until the end of the experiment. ZM214385 was dissolved in DMSO (10 mg/145 μl of DMSO) and then further diluted in 14.8 ml of PBS, yielding a 2 mM working concentration of which a volume of approximately 250–300 μl was injected per mouse. Control animals received the same volume of the solvents only. ZM214385 or control solution were injected subcutaneously 30 min before IT LPS administration. According to the pharmacokinetics of subcutaneously injected ZM214385 at 10 mg/kg body weight, plasma concentrations of the antagonist were higher than 50 nM, even 6 h after its administration. This concentration of ZM214385 is sufficient to exert maximum pharmacologic antagonism on the adenosine-induced cAMP response in murine thymocytes (for determination of pharmacokinetics of ZM214385 see also “Modulation and measurement of cAMP production of PMNs by A2AR stimulation and antagonism in vitro,” below).

**Control of fraction of inspired oxygen.** In order to modify the fraction of inspired oxygen, mice were placed in airtight modular incubation chambers (Billups-Rothenberg, San Diego, California, United States), and the atmosphere was controlled by a constant gas flow (1.5 l/min) of desired composition (10 % O2, 60 % N2, or 100% O2). To prevent any CO2 retention in the chambers, the chambers' bottom was covered with approximately 250 g of anesthetic CO2 absorber material (Sodasorb, Grace & Co, Chicago, Illinois, United States). Composition of gas atmosphere was tested intermittently by analyzing pCO2 and pO2 values in an equilibrated fluid sample drawn from a tube inside the chamber whenever the latter was opened for reinjection of mice. During the stay of mice in chambers, animals were fed and given fluids by offering them Transgel (Charles River Laboratories, Wilmington, Massachusetts, United States).

**Assessment of lung gas exchange and oxygen tension in peripheral blood.** At the end of the experiments, arterial blood specimen from the tail artery were sampled directly into heparinized glass capillaries that were closed on both ends with Parafilm and kept on ice until further analysis (Rapidlab 248 system; Chiron Diagnostics, Essex, United Kingdom).

**Histological analysis.** IT LPS-injected mice were sacrificed by...
isoflurane anesthesia, and the trachea was surgically exposed and cannulated with a 20-gauge needle. The thoracic cage was opened to allow lungs to expand during injection of 1 ml of 4% paraformalde- hyde. After 15 min, the lungs were removed and fixed in 4% paraformaldehyde until processing and H&E staining (American Histolabs, Washington, Maryland). Quantitative analysis of lung neutrophil accumulation was performed by histomorphometric analysis [49], and lung tissue injury was semiquantitatively assessed in a blinded fashion by a professional pathologist (I. Bittmann, MD). Lung slices of IT LPS-injected groups of mice were first assessed for pathological changes in general, enabling identification of lung inflammation parameters to be further evaluated in a semiquantitative way by assignment of four degrees of increasing severity. Overall assessment of slides showed acute blood congestion, intra- septal and intraalveolar neutrophil sequestoration, interstitial edema, intraalveolar macrophage accumulation, pneumocyte type II activation, endothelial cell activation, and endothelial adherence of leukocytes. No intraalveolar edema and no fibrin deposits were observed. Lung tissue injury was then evaluated by assignment of four degrees of severity (0–3) to the following parameters in H&E stained lung slides: interstitial edema formation, intraalveolar macrophage accumulation, pneumocyte activation, endothelial cell activation, and leukocyte adhesion to endothelial cells. The lung injury score of each lung slice was calculated as an average of each parameter’s degree of severity, ranging from 0 for a healthy lung to 15 (maximal severity) for maximally injured lung. Further details on definition of degrees of severity of pathological changes of each parameter are described in Table 1.

**BAL and cellular differentials.** Following sacrifice and surgical preparation of mice as outlined above for histological analysis, except the opening of the thoracic cavity, lungs were lavaged by injection of 0.5 mL of HBSS, which after each collection was repeated four times. The recovered (over 90%) BAL fluid was processed for total cell counts and cellular differentials. Contaminating erythrocytes were lysed by 0.01% saponin, and total leukocytes counted with a Neubauer chamber. Differential counts were performed after cytospin onto glass slides and staining with Hema-3 stain. The remaining bronchoalveolar fluid was spun down and the supernatant collected for determination of protein concentration using the Bio-

**Flow cytometric determination of hydrogen peroxide production by activated PMNs.** BAL cells or whole blood, the latter withdrawn from the tail vein and diluted in ice-cold heparinized (40 U/mL) HBSS, were washed two times with HBSS (0 °C). Cell pellets were resuspended in HBSS containing dihydrodorhamine (2.5 μM). For measurement of spontaneous hydrogen peroxide production by oxidation of dihydrodorhamine to fluorescent rhodamine, cells were either not incubated or incubated at 37 °C for 30 min and thereafter to ice. In parallel experiments designed to test the effects of CGS21680 on blood granulocytes, cells were preincubated with LPS (10 μg/mL) in the absence or presence of the A2aR agonist for 15 min, then stimulated by addition of the chemotactic tripeptide fMLP (10 μM). When pharmacologic effects of CGS21680 were tested on BAL granulocytes, no LPS was added. Cells were washed two times with ice-cold PBS that contained bovine serum albumin (0.5%). FcgII/ III receptors were blocked by anti-mouse CD16/CD32 (10 min, 1 mg/mL) and isotype control antibody were obtained from Caltag Laboratories (Oregon, United States). PE-labeled anti-mouse Ly6G (Gr-1) antibody and isotype control antibody were obtained from Beckman Coulter (Brea, California, United States). Fc-receptor-blocking anti-CD16/CD32 antibodies were purchased from BD Biosciences Pharmingen (San Diego, California, United States). Hema 3 stain for white blood cells and differential counts was purchased from Fisher Scientific (Suwanee, Georgia, New York, United States). Dye reagent concentrate for protein detection was obtained from Bio-Rad Laboratories. A2aR-selective agonist CGS21680 and antagonist ZM241385 were purchased fromSigma Chemicals (St. Louis, Missouri, United States) and supplemented by 1 mM MgCl2 and 1 mM CaCl2 freshly before use. Dihydrodorhamine was purchased from Molecular Probes (Eugene, Oregon, United States). PE-labeled anti-mouse Ly6G (Gr-1) antibody and isotype control antibody were obtained from Becton Dickinson (Mountain View, California, United States). Isoflurane was obtained from Baxter (Deerfield, Illinois, United States). All other chemicals were purchased from Sigma Chemicals.

**Statistics.** Data are represented as individual values. In the graphs, the horizontal lines give the means of the individual values. Comparison between independent samples was performed by two-tailed nonparametric Mann-Whitney test. To test for the strength of the relationship between two variables, linear regression analysis was performed and Pearson correlation coefficients calculated. Differences between survival rates were tested by Chi2 test.

**Acknowledgments.** The authors wish to thank Dr. William Paul for support, discussions, and help. MT was a visiting National Institutes of Health Fogarty Fellow on leave from the Clinic of Anesthesiology, Klinikum Grosshadern, University of Munich, and was partially supported by a grant from the German National Research Foundation to MT, TH7392.

**Competition of interest.** The authors have declared that no competing interests exist.

**Author contributions.** MT and MVS conceived and designed the experiments. MT, AC, AO, EJ, CC, and PS performed the experiments. DL and IB analyzed the data. MT and MVS wrote the paper.
Oxygen Exacerbates Acute Lung Injury

References

inhibition of adenosine kinase potentiates cardiac adenosine release. Circ
Endogenous adenosine produced during hypoxia accentuates neutrophil
accumulation. Coordination by extracellular nucleotide metabolism. Blood
104: 3986–3992.
plasma concentration as a prognostic index for outcome in patients with
Physiological control of immune response and inflammatory tissue damage
by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev
11. Linden J (2001) Molecular approach to adenosine receptors: Receptor-
mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol
41: 775–787.
A2A receptors in downregulation of inflammation and protection from tissue damage.
Adenosine A2A receptor deficiency attenuates brain injury induced by transient focal
inhibition of adenosine kinase potentiates cardiac adenosine release. Circ
Oxyradical signaling. Am J Physiol Regul Integr Comp Physiol 287: R437–
R445.
278: 13011–13018.
Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775–787.